Indian Pharmacopoeia 2026 adds 121 monographs, introduces blood component standards

Source report date: 2026-01-02. This digest summarises that dated announcement.

Union Health Minister J. P. Nadda launched Indian Pharmacopoeia 2026, the tenth edition of India’s official drug standards book, in New Delhi on January 2, 2026, according to a Ministry of Health and Family Welfare release. The Indian Pharmacopoeia Commission publishes the book on the ministry’s behalf to meet requirements under the Drugs and Cosmetics Act, 1940.

The edition adds 121 monographs, bringing the total to 3,340, Nadda said. Coverage has expanded for anti-tubercular, anti-diabetic and anti-cancer medicines, alongside iron supplements. According to the minister, these additions broaden standardisation for medicines used in National Health Programmes. The edition also includes, for the first time, 20 blood component monographs covering transfusion medicine, in line with the Drugs and Cosmetics (Second Amendment) Rules, 2020.

Nadda said the Indian Pharmacopoeia is recognised in 19 Global South countries. He also reported that India ranked eighth in 2025 for contributions to the World Health Organization’s pharmacovigilance database, compared with 123rd during 2009–2014. He linked this progress to the Pharmacovigilance Programme of India under the commission.

According to the ministry, Indian Pharmacopoeia standards are legally enforceable and apply to drugs manufactured or marketed in India. The release also describes collaboration with the European, Japanese and United States pharmacopoeias to harmonise monographs and general chapters, and says its general requirements have been aligned with International Council for Harmonisation standards.